|
1
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 14:160182016. View Article : Google Scholar
|
|
2
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. The Lancet. 391:1301–1314. 2018.
View Article : Google Scholar
|
|
3
|
Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC
and Yen Y: Cancers in Taiwan: Practical insight from epidemiology,
treatments, biomarkers, and cost. J Formos Med Assoc.
119:1731–1741. 2020. View Article : Google Scholar
|
|
4
|
Polesel J, Zucchetto A, Montella M, Dal
Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S and
Talamini R: The impact of obesity and diabetes mellitus on the risk
of hepatocellular carcinoma. Ann Oncol. 20:353–357. 2009.
View Article : Google Scholar
|
|
5
|
Li S, Saviano A, Erstad DJ, Hoshida Y,
Fuchs BC, Baumert T and Tanabe KK: Risk factors, pathogenesis, and
strategies for hepatocellular carcinoma prevention: Emphasis on
secondary prevention and its translational challenges. J Clin Med.
9:38172020. View Article : Google Scholar :
|
|
6
|
Bosch FX, Ribes J, Cléries R and Díaz M:
Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
9:191–211. 2005. View Article : Google Scholar
|
|
7
|
Dash S, Aydin Y, Widmer KE and Nayak L:
Hepatocellular carcinoma mechanisms associated with chronic HCV
infection and the impact of direct-acting antiviral treatment. J
Hepatocell Carcinoma. 7:45–76. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sung PS and Shin EC: Immunological
mechanisms for hepatocellular carcinoma risk after direct-acting
antiviral treatment of hepatitis C virus infection. J Clin Med.
10:2212021. View Article : Google Scholar :
|
|
9
|
Andrisani O: Epigenetic mechanisms in
hepatitis B virus-associated hepatocellular carcinoma. Hepatoma
Res. 7:122021.PubMed/NCBI
|
|
10
|
Ulcickas Yood M, Quesenberry CP Jr, Guo D,
Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Caldwell C and
Manos MM: Incidence of hepatocellular carcinoma among individuals
with heaptitis B virus infection identified using an automated data
algorithm. J Viral Hepat. 15:28–36. 2008.
|
|
11
|
Fattovich G, Stroffolini T, Zagni I and
Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk
factors. Gastroenterology. 127(5 Suppl 1): S35–S50. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nguyen VT, Law MG and Dore GJ: Hepatitis
B-related hepatocellular carcinoma: Epidemiological characteristics
and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim GA, Lim YS, Han S, Choi J, Shim JH,
Kim KM, Lee HC and Lee YS: High risk of hepatocellular carcinoma
and death in patients with immune-tolerant-phase chronic hepatitis
B. Gut. 67:945–952. 2018. View Article : Google Scholar
|
|
14
|
Pons F, Varela M and Llovet JM: Staging
systems in hepatocellular carcinoma. HPB (Oxford). 7:35–41. 2005.
View Article : Google Scholar
|
|
15
|
Mak LY, Cruz-Ramó V, Chinchilla-López P,
Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK,
Bailey HH, et al: Global epidemiology, prevention, and management
of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book.
38:262–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haxho F, Allison S, Alghamdi F, Brodhagen
L, Kuta VE, Abdulkhalek S, Neufeld RJ and Szewczuk MR: Oseltamivir
phosphate monotherapy ablates tumor neovascularization, growth, and
metastasis in mouse model of human triple-negative breast
adenocarcinoma. Breast Cancer (Dove Med Press). 6:191–203.
2014.
|
|
17
|
Xu HZ, Liu YP, Guleng B and Ren JL:
Hepatitis B virus-related hepatocellular carcinoma: Pathogenic
mechanisms and novel therapeutic interventions. Gastrointest
Tumors. 1:135–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Levy JM and Thorburn A: Targeting
autophagy during cancer therapy to improve clinical outcomes.
Pharmacol Ther. 131:130–141. 2011. View Article : Google Scholar
|
|
19
|
Chen C, Gao H and Su X: Autophagy-related
signaling pathways are involved in cancer (Review). Exp Ther Med.
22:7102021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee XC, Werner E and Falasca M: Molecular
mechanism of autophagy and its regulation by cannabinoids in
cancer. Cancers (Basel). 13:12112021. View Article : Google Scholar
|
|
21
|
Islam Khan MZ and Law HK: Cancer
Susceptibility Candidate 9 (CASC9) promotes colorectal cancer
carcinogenesis via mTOR-dependent autophagy and
epithelial-mesenchymal transition pathways. Front Mol Biosci.
8:6270222021. View Article : Google Scholar
|
|
22
|
Khurana A, Roy D, Kalogera E, Mondal S,
Wen X, He X, Dowdy S and Shridhar V: Quinacrine promotes autophagic
cell death and chemosensitivity in ovarian cancer and attenuates
tumor growth. Oncotarget. 6:36354–36369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Wu J, Fan M, Shen C, Dai W, Bao Y,
Liu JH and Yu BY: Novel dihydroartemisinin derivative DHA-37
induces autophagic cell death through upregulation of HMGB1 in A549
cells. Cell Death Dis. 9:10482018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang K, Zhou X, Wang J, Zhou Y, Qi W,
Chen H, Nie S and Xie M: Dendrobium officinale polysaccharide
triggers mitochondrial disorder to induce colon cancer cell death
via ROS-AMPK-autophagy pathway. Carbohydr Polym. 264:1180182021.
View Article : Google Scholar
|
|
25
|
Armando RG, Mengual Gómez DL and Gomez DE:
New drugs are not enough-drug repositioning in oncology: An update.
Int J Oncol. 56:651–684. 2020.PubMed/NCBI
|
|
26
|
Nunes M, Henriques Abreu M, Bartosch C and
Ricardo S: Recycling the purpose of old drugs to treat ovarian
cancer. Int J Mol Sci. 21:77682020. View Article : Google Scholar :
|
|
27
|
Hampson L, Maranga IO, Masinde MS, Oliver
AW, Batman G, He X, Desai M, Okemwa PM, Stringfellow H,
Martin-Hirsch P, et al: A single-arm, proof-of-concept trial of
Lopimune (Lopinavir/Ritonavir) as a treatment for HPV-related
pre-invasive cervical disease. PLoS One. 11:e01479172016.
View Article : Google Scholar :
|
|
28
|
Beaucourt S and Vignuzzi M: Ribavirin: A
drug active against many viruses with multiple effects on virus
replication and propagation. Molecular basis of ribavirin
resistance. Curr Opin Virol. 8:10–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Daughton CG and Ruhoy IS: Lower-dose
prescribing: Minimizing 'side effects' of pharmaceuticals on
society and the environment. Sci Total Environ. 443:324–337. 2013.
View Article : Google Scholar
|
|
30
|
von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tan S, Liu X, Chen L, Wu X, Tao L, Pan X,
Tan S, Liu H, Jiang J and Wu B: Fas/FasL mediates
NF-kappaBp65/PUMA-modulated hepatocytes apoptosis via autophagy to
drive liver fibrosis. Cell Death Dis. 12:4742021. View Article : Google Scholar
|
|
32
|
Alvarez-Meythaler JG, Garcia-Mayea Y, Mir
C, Kondoh H and LLeonart ME: Autophagy takes center stage as a
possible cancer hallmark. Front Oncol. 10:5860692020. View Article : Google Scholar
|
|
33
|
Buzun K, Gornowicz A, Lesyk R, Bielawski K
and Bielawska A: Autophagy modulators in cancer therapy. Int J Mol
Sci. 22:58042021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsu IC, Tokiwa T, Bennett W, Metcalf RA,
Welsh JA, Sun T and Harris CC: p53 gene mutation and integrated
hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis. 14:987–992. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duffy MJ, Synnott NC and Crown J: Mutant
p53 as a target for cancer treatment. Eur J Cancer. 83:258–265.
2017. View Article : Google Scholar
|
|
36
|
Braithwaite AW, Royds JA and Jackson P:
The p53 story: Layers of complexity. Carcinogenesis. 26:1161–1169.
2005. View Article : Google Scholar
|
|
37
|
Berns EM, van Staveren IL, Look MP, Smid
M, Klijn JG and Foekens JA: Mutations in residues of TP53 that
directly contact DNA predict poor outcome in human primary breast
cancer. Br J Cancer. 77:1130–1136. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rossner P Jr, Gammon MD, Zhang YJ, Terry
MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G,
Agrawal M, et al: Mutations in p53, p53 protein overexpression and
breast cancer survival. J Cell Mol Med. 13:3847–3857. 2009.
View Article : Google Scholar
|
|
39
|
Guo JY and White E: Autophagy, metabolism,
and cancer. Cold Spring Harb Symp Quant Biol. 81:73–78. 2016.
View Article : Google Scholar
|
|
40
|
Shi K, An J, Qian K, Zhao X, Li F, Ma X,
Wang Y and Zhang Y: p53 controls the switch between autophagy and
apoptosis through regulation of PLSCR1 in sodium selenite-treated
leukemia cells. Exp Cell Res. 389:1118792020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Itakura E and Mizushima N: p62 Targeting
to the autophagosome formation site requires self-oligomerization
but not LC3 binding. J Cell Biol. 192:17–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Islam MA, Sooro MA and Zhang P: Autophagic
Regulation of p62 is critical for cancer therapy. Int J Mol Sci.
19:14052018. View Article : Google Scholar :
|
|
43
|
Moscat J, Diaz-Meco MT and Wooten MW:
Signal integration and diversification through the p62 scaffold
protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar
|
|
44
|
Ichimura Y, Kominami E, Tanaka K and
Komatsu M: Selective turnover of p62/A170/SQSTM1 by autophagy.
Autophagy. 4:1063–1066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin X, Li S, Zhao Y, Ma X, Zhang K, He X
and Wang Z: Interaction domains of p62: A bridge between p62 and
selective autophagy. DNA Cell Biol. 32:220–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Young MM, Takahashi Y, Khan O, Park S,
Hori T, Yun J, Sharma AK, Amin S, Hu CD and Zhang J: Autophagosomal
membrane serves as platform for intracellular death-inducing
signaling complex (iDISC)-mediated caspase-8 activation and
apoptosis. J Biol Chem. 287:12455–12468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sanz L, Diaz-Meco MT, Nakano H and Moscat
J: The atypical PKC-interacting protein p62 channels NF-kappaB
activation by the IL-1TRAF6 pathway. EMBO J. 19:1576–1586. 2000.
View Article : Google Scholar
|
|
48
|
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC,
Lill JR and Ashkenazi A: Cullin3-based polyubiquitination and
p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis
signaling. Cell. 137:721–735. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cooper NJ, Sutton AJ, Abrams KR, Wailoo A,
Turner D and Nicholson KG: Effectiveness of neuraminidase
inhibitors in treatment and prevention of influenza A and B:
Systematic review and meta-analyses of randomised controlled
trials. BMJ. 326:12352003. View Article : Google Scholar :
|
|
50
|
Hayden FG, Treanor JJ, Fritz RS, Lobo M,
Betts RF, Miller M, Kinnersley N, Mills RG, Ward P and Straus SE:
Use of the oral neuraminidase inhibitor oseltamivir in experimental
human influenza: Randomized controlled trials for prevention and
treatment. JAMA. 282:1240–1246. 1999. View Article : Google Scholar
|
|
51
|
O'Shea LK, Abdulkhalek S, Allison S,
Neufeld RJ and Szewczuk MR: Therapeutic targeting of Neu1 sialidase
with oseltamivir phosphate (Tamiflu) disables cancer cell survival
in human pancreatic cancer with acquired chemoresistance. Onco
Targets Ther. 7:117–134. 2014.
|
|
52
|
Kong F, Li N, Tu T, Tao Y, Bi Y, Yuan D,
Zhang N, Yang X, Kong D, You H, et al: Hepatitis B virus core
protein promotes the expression of neuraminidase 1 to facilitate
hepatocarcinogenesis. Lab Invest. 100:1602–1617. 2020. View Article : Google Scholar : PubMed/NCBI
|
